MD3226842T2 - Compoziții anticancer - Google Patents

Compoziții anticancer

Info

Publication number
MD3226842T2
MD3226842T2 MDE20170153T MDE20170153T MD3226842T2 MD 3226842 T2 MD3226842 T2 MD 3226842T2 MD E20170153 T MDE20170153 T MD E20170153T MD E20170153 T MDE20170153 T MD E20170153T MD 3226842 T2 MD3226842 T2 MD 3226842T2
Authority
MD
Moldova
Prior art keywords
rna
prostate cancer
meth
poly
acrylate copolymer
Prior art date
Application number
MDE20170153T
Other languages
English (en)
Inventor
Geert Verreck
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3226842(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of MD3226842T2 publication Critical patent/MD3226842T2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Prezenta invenţie se referă la formulări farmaceutice de ARN-509, care pot fi administrate unui mamifer, în special un om, care suferă de o boală sau afecţiune legată de receptorul androgen (AR), în special cancer, mai ales cancer de prostată, inclusiv dar nu se limitează la cancer de prostată rezistent la castrare, cancer de prostată rezistent la castrare metastatică, cancer de prostată rezistent la castrare metastatică fără chimioterapie, cancer de prostată sensibil la hormoni recidivat biochimic sau cancer de prostată rezistent la castrare non-metastatic. Într-un aspect, aceste formulări cuprind o dispersie solidă de ARN-509 şi un copolimer poli (met) acrilat. Într-un aspect, dispersia solidă a ARN-509 şi a unui copolimer poli (met) acrilat este obţinută, în particular se obţine, prin extrudarea prin topire a unui amestec cuprinzând ARN-509 şi un copolimer poli (met) acrilat şi măcinând opţional amestecul topit-extrudat menţionat. Într-un aspect, dispersia solidă a ARN-509 şi a unui copolimer poli (met) acrilat este obţinută, în particular se obţine prin uscarea prin pulverizare a unui amestec cuprinzând ARN-509 şi un copolimer poli (met) acrilat într-un solvent adecvat.
MDE20170153T 2014-12-05 2015-12-03 Compoziții anticancer MD3226842T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196591 2014-12-05
PCT/US2015/063667 WO2016090101A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (1)

Publication Number Publication Date
MD3226842T2 true MD3226842T2 (ro) 2021-03-31

Family

ID=52006905

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20170153T MD3226842T2 (ro) 2014-12-05 2015-12-03 Compoziții anticancer

Country Status (31)

Country Link
US (2) US20170360707A1 (ro)
EP (2) EP3226842B1 (ro)
JP (1) JP6767368B2 (ro)
KR (1) KR102348325B1 (ro)
CN (2) CN106999430A (ro)
AR (1) AR102924A1 (ro)
AU (1) AU2015358493B2 (ro)
CA (1) CA2969661C (ro)
CL (1) CL2017001372A1 (ro)
CO (1) CO2017005573A2 (ro)
CR (1) CR20170217A (ro)
CY (1) CY1123856T1 (ro)
DK (1) DK3226842T3 (ro)
EA (1) EA035988B1 (ro)
ES (1) ES2839128T3 (ro)
HR (1) HRP20201902T1 (ro)
HU (1) HUE051888T2 (ro)
IL (1) IL252324B (ro)
LT (1) LT3226842T (ro)
MA (2) MA41108B1 (ro)
MD (1) MD3226842T2 (ro)
MX (1) MX2017007201A (ro)
NI (1) NI201700069A (ro)
PL (1) PL3226842T3 (ro)
PT (1) PT3226842T (ro)
RS (1) RS61466B1 (ro)
SG (1) SG11201704264UA (ro)
SI (1) SI3226842T1 (ro)
TW (1) TWI683662B (ro)
UA (1) UA121123C2 (ro)
WO (1) WO2016090101A1 (ro)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2885415C (en) 2012-09-26 2021-06-29 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
ES2883187T3 (es) 2014-12-05 2021-12-07 Aragon Pharmaceuticals Inc Composiciones anticancerosas
EP3697398A1 (en) 2017-10-16 2020-08-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
EP3773509B1 (en) 2018-04-06 2023-11-01 Capsugel Belgium NV Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
WO2020144649A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising enzalutamide dispersed in apple sauce
CA3128331A1 (en) 2019-01-30 2020-08-06 Margaret K. YU Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
JP2022524289A (ja) 2019-01-30 2022-05-02 ヤンセン ファーマシューティカ エヌ．ベー． 分子サブタイプに基づいて前立腺癌を治療する方法
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN115666565A (zh) 2019-11-04 2023-01-31 阿拉贡药品公司 用于治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008999A (es) 2001-04-02 2004-02-12 Astrazeneca Ab Composicion farmaceutica solida que comprende 4-ciano -trifluor-3 -(4-fluorfenilsulfonil) -2-hidroxi-2 -metilpropino -m-toluidida y pvp.
WO2003077827A1 (fr) * 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Procede de production de medicament solide en dispersion
EP1694302A1 (en) * 2003-12-15 2006-08-30 Council of Scientific and Industrial Research TASTE MASKED PHARMACEUTICAL COMPOSITIONS COMPRISING BITTER DRUG AND pH SENSITIVE POLYMER
PL2368550T3 (pl) * 2006-03-27 2014-01-31 Univ California Modulator receptorów androgenowych do leczenia raka gruczołu krokowego i chorób związanych z receptorami androgenów
EP3124481B1 (en) * 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US10071945B2 (en) * 2011-06-15 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
JP6182209B2 (ja) 2012-06-07 2017-08-16 アラゴン ファーマシューティカルズ，インコーポレイテッド アンドロゲン受容体変調剤の結晶質形態
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
CN105358535B (zh) * 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
CA2885415C (en) * 2012-09-26 2021-06-29 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
MY192032A (en) * 2013-01-22 2022-07-24 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
RU2016104643A (ru) * 2013-08-12 2017-09-19 Токай Фармасьютикалз, Инк. Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения
US20160346207A1 (en) * 2014-02-05 2016-12-01 Lek Pharmaceuticals D.D. Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists

Also Published As

Publication number Publication date
CR20170217A (es) 2017-08-30
EP3226842A1 (en) 2017-10-11
CA2969661C (en) 2023-04-25
RS61466B1 (sr) 2021-03-31
IL252324A0 (en) 2017-07-31
MA41108B1 (fr) 2021-03-31
NI201700069A (es) 2017-10-31
DK3226842T3 (da) 2021-01-25
MA55404A (fr) 2022-02-02
MA41108A (fr) 2016-06-09
CO2017005573A2 (es) 2017-09-29
CL2017001372A1 (es) 2018-01-05
CN115837010A (zh) 2023-03-24
MX2017007201A (es) 2018-01-30
CA2969661A1 (en) 2016-06-09
AU2015358493B2 (en) 2021-05-06
UA121123C2 (uk) 2020-04-10
EA201791252A1 (ru) 2017-10-31
KR102348325B1 (ko) 2022-01-06
JP2017536401A (ja) 2017-12-07
SI3226842T1 (sl) 2021-04-30
EA035988B1 (ru) 2020-09-09
ES2839128T3 (es) 2021-07-05
CN106999430A (zh) 2017-08-01
AU2015358493A1 (en) 2017-06-08
SG11201704264UA (en) 2017-06-29
BR112017011787A2 (pt) 2017-12-26
PT3226842T (pt) 2020-12-23
HUE051888T2 (hu) 2021-03-29
EP3842034A1 (en) 2021-06-30
KR20170086657A (ko) 2017-07-26
WO2016090101A1 (en) 2016-06-09
IL252324B (en) 2021-10-31
TWI683662B (zh) 2020-02-01
HRP20201902T1 (hr) 2021-07-23
US20170360707A1 (en) 2017-12-21
US20220151931A1 (en) 2022-05-19
EP3226842B1 (en) 2020-11-25
TW201632187A (zh) 2016-09-16
JP6767368B2 (ja) 2020-10-14
AR102924A1 (es) 2017-04-05
PL3226842T3 (pl) 2021-07-12
CY1123856T1 (el) 2022-05-27
LT3226842T (lt) 2021-03-25

Similar Documents

Publication Publication Date Title
MD3226842T2 (ro) Compoziții anticancer
PH12017500979A1 (en) Anticancer compositions
MX2021013965A (es) Composiciones anticancerigenas.
PH12016501791A1 (en) Muscarinic receptor agonists
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
WO2015095404A3 (en) Methods of treating cancers using pd-1 axis binding antagonists and taxanes
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
EA033197B1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
GEP20196961B (en) 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139
MX2018003563A (es) Nuevos compuestos.
PH12018502334A1 (en) Anticancer compositions
MX2020000135A (es) Nuevos compuestos de quinolinona.
EP3287135A4 (en) THERAPEUTIC AGENT FOR THE INHIBITION OF TUMOR PROLIFERATION AND METASTASIS, COMPRISING EXOSOMES RELEASED BY CYTOTOXIC T CELLS AND TARGETING STROMAL / MESENCHYMAL CANCER CELLS
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF